NCT02029001 2025-08-07
MOST plus
Centre Leon Berard
Phase 2 Recruiting
Clinical Trials
15 trialsNCT01543763 2025-03-21
Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors
University of California, San Francisco
Phase 1 Completed
NCT02066285 2023-03-27
Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid Chondrosarcoma
Grupo Espanol de Investigacion en Sarcomas
Phase 2 Completed
NCT01392183 2021-09-20
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02959554 2021-09-08
NIVOSWITCH
AIO-Studien-gGmbH
Phase 2 Terminated
NCT01221506 2020-03-26
Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)
Abramson Cancer Center at Penn Medicine
Phase EARLY_PHASE1 Completed
NCT01442662 2020-01-31
LMS03
UNICANCER
Phase 2 Completed
NCT02795819 2019-10-24
Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer
Virginia Commonwealth University
Phase 1 Terminated
NCT01642017 2018-08-06
VOTRAGE
Institut Claudius Regaud
Phase 1 Terminated
NCT01385228 2018-06-06
Pazopanib, Docetaxel, Prednisone Prostate
Duke University
Phase 1 Completed
NCT03149120 2017-08-22
Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas
NYU Langone Health
Phase 2 Withdrawn
NCT01108055 2017-06-09
Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer
Stanford University
Phase 2 Completed
NCT01130805 2016-04-15
A Study of Pazopanib With CAPEOX in AGC Patients
Samsung Medical Center
Phase 2 Completed
NCT01542047 2015-06-18
A Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies
New Mexico Cancer Research Alliance
Phase 1 Terminated
NCT00731211 2015-05-20
Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma
SCRI Development Innovations, LLC
Phase 2 Completed